


Ask a doctor about a prescription for COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION
Prospect:information for the user
COLIROFTA ATROPINA 10 mg/ml eye drops in solution
Read the entire prospectus carefully before starting to use this medication, as it contains important information for you.
|
Contents of the prospectus
5 Conservation of COLIROFTA ATROPINA 10 mg/ml
It is an eye drop that contains atropine, an anticholinergic agent (blocks some of the acetylcholine receptors, a neurotransmitter) that, when administered in the eyes, produces mydriasis (pupil dilation) and cycloplegia (paralysis of the muscle that produces accommodation).
Colirofta Atropina 10 mg/ml is indicated:
Do not use COLIROFTA ATROPINA 10 mg/ml
(See section 2, "Pregnancy, breastfeeding, and fertility").
Warnings and precautions
Consult your doctor or pharmacist before starting to use Colirofta Atropina 10 mg/ml.
It may cause an increase in blood pressure.
Children
Other medications and COLIROFTA ATROPINA 10 mg/ml
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.
Especially, tell your doctor if you are using:
Medications that share properties with the active ingredient of the medication, such as:
Other medications:
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
This medication is not recommended during pregnancy or breastfeeding.
Driving and using machines
The influence of this medication on the ability to drive and use machines is significant.
This medication can cause blurred vision and sensitivity to light for a prolonged period, which can last several days. Do not drive or use machines or tools until your vision is clear.
COLIROFTA ATROPINA 10 mg/ml containsmethylparahydroxybenzoate (E-218) and propylparahydroxybenzoate (E-216) and phosphates
This medication may cause allergic reactions (possibly delayed) because it contains methylparahydroxybenzoate (E-218) and propylparahydroxybenzoate (E-216).
This medication contains 6 mg of phosphates per ml.
If you have severe corneal damage (the transparent layer of the front of the eye), treatment with phosphates, in very rare cases, can cause blurred vision due to calcium accumulation.
Follow the administration instructions of this medication indicated by your doctor or pharmacist exactly. If in doubt, consult your doctor or pharmacist again.
The recommended dose is:
Adults
When a sustained effect is intended, three daily applications of 2 drops are usually performed.
For refraction examination, 1 or 2 drops will be instilled in each eye twice a day, 1 to 3 days before the examination.
Use in children
Children (over 3 years of age)
Due to the risk of producing severe systemic adverse effects, this medication is contraindicated in children under 3 years of age and is recommended to be used with caution in children over 3 years. The lowest effective dose possible is recommended to reduce the risk of systemic adverse effects (see "Warnings and precautions").
When a sustained effect is intended, three daily applications of 1 drop are usually performed.
For refraction examination, 1 or 2 drops will be instilled in each eye twice a day, 1 to 3 days before the examination.
Remember to apply your medication according to your doctor's instructions.
Use in elderly patients
Use with caution in elderly patients, as they may have a higher risk of undiagnosed glaucoma and behavioral disorders.
Your doctor will indicate the duration of your treatment with Colirofta Atropina 10 mg/ml. Do not stop treatment before, unless your doctor indicates it.
Recommendations for use:
Ophthalmic route (in the eyes).

1 2 3
If a drop falls outside the eye, try again.
If you are using other ophthalmic medications, wait at least 5 minutes between the administration of this eye drop and other ophthalmic medications. Ophthalmic ointments should be administered last.
If you use more COLIROFTA ATROPINA 10 mg/ml than you should
You can eliminate it by washing your eyes with warm water. Do not apply more drops until it is time for your next dose. The symptoms of overdose may include redness and dryness of the skin (in children, it may present as a rash), blurred vision, rapid and irregular pulse, fever, abdominal swelling in children, convulsions, hallucinations, loss of coordination, and rapid progressive respiratory depression.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service. Phone: 91 562 04 20, indicating the medication and the amount used.
If you forget to use COLIROFTA ATROPINA 10 mg/ml
Do not apply a double dose to make up for forgotten doses.
Apply a single dose as soon as you remember and continue with the next dose that was scheduled. However, if it is almost time for the next dose, do not apply the forgotten dose and continue with the next dose of your regular regimen.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause adverse effects, although not all people experience them.
The following reactions have been reported during post-marketing experience:
Frequency not known(cannot be estimated from the available data):
Other adverse effects in children
Children are more likely to exhibit the general adverse effects described above, especially in premature children and those with low birth weight or patients with Down syndrome, spastic paralysis, or brain injury (see section 2, "Do not use...").
Reporting adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: https://www.notificaRAM.es.By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Store below 25°C.
Do not use this medication after the expiration date that appears on the bottle and on the box after EXP. The expiration date is the last day of the month indicated.
To avoid infections, the bottle must be discarded 4 weeks after it was first opened.
Write the opening date of the bottle in the box provided for this purpose.
Medications should not be thrown away in drains or trash. Deposit the packaging and medications you no longer need in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This way, you will help protect the environment.
Composition of COLIROFTA ATROPINA 10 mg/ml
Appearance of the product and contents of the package
Colirofta Atropina 10 mg/ml is an eye drop solution; it is a clear and colorless liquid that comes in a 10 ml dropper bottle (plastic bottle) with a sealed cap.
Marketing authorization holder and manufacturer
Marketing authorization holder
Alcon Healthcare S.A.
World Trade Center Almeda Park
Plaça de la Pau s/n, Edificio 6, planta 3
08940 - Cornellà de Llobregat (Barcelona)
Spain
Manufacturer
Siegfried El Masnou, S.A.
C/ Camil Fabra, 58
08320 El Masnou – Barcelona
Spain
or
Alcon Laboratories Belgium
Lichterveld 3
2870 Puurs-Sint-Amands
Belgium
Date of the last revision of this prospectus:May 2020
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es
The average price of COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION in October, 2025 is around 5.39 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for COLIROFTA ATROPINE 10 mg/ml EYE DROPS SOLUTION – subject to medical assessment and local rules.